MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
KYTX — Kyverna Therapeutics, Inc. Common Stock
NasdaqKyverna Therapeutics, Inc. Common Stock
$6.32
+0.10(+1.61%)
- O
- 6.30
- H
- 6.44
- L
- 6.00
- V
- 813.22K
⏱️ End-of-day dataAs of Oct 5, 2026
Chart
About KYTX
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateFeb 8, 2024
Employees149
Stock ExchangeNasdaq
Ticker SymbolKYTX
Websitehttps://www.kyvernatx.com
Key Financial Statistics
| Market Cap | $384.67M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $5.30 - $13.67 |
| 52-Week Avg Volume | 1.06M |
| VWAP | $6.25 |
| Transactions | 10,672 |
| Total Recorded Bars | 666 days |